Completed PHASE2 INTERVENTIONAL 1-arm NCT00221026

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease

A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents

Sponsor: ICON plc

Conditions Crohn's Disease

Interventions Extracorporeal Photopheresis Methoxsalen +ECP

Updated 7 times since 2017 Last updated: Oct 18, 2016 Started: Dec 31, 2004 Primary completion: Jun 30, 2006 Completion: Jun 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Crohn's Disease, this trial is completed. The trial is conducted by ICON plc and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ICON plc
Mallinckrodt

Data source: Mallinckrodt

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bethesda, United States , Bochum, Germany , Brussels, Belgium , Chevy Chase, United States , Düren, Germany , Essen, Germany , Jena, Germany , Leuven, Belgium , Mannheim, Germany , Morristown, United States and 5 more locations